A report released Tuesday by US Senators Ron Wyden and Charles Grassley claims that Gilead Sciences priced the hepatitis C treatments Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) with the sole goal of maximising revenue. The report was based on an investigation of 20 000 pages of internal company documents, dozens of interviews with health care experts and data from Medicaid programmes in all 50 states and the District of Columbia.

You can read an overview here:

http://hepatitiscnewdrugs.blogspot.com.au/2015/12/sovaldi-investigation-finds-revenue.html

The report in full is available here

An executive summary is available here.

A timeline of events pertaining to Gilead, Sovaldi and Harvoni is available here

A glossary of terms pertaining to the investigation is available here

Letters from state Medicaid programs are available here